New York Times Company (The) (NYSE:NYT)
New York Times Company (The) (NYSE:NYT) represented a move of -5.62 percent or $1.4 per share and closed its previous day trading session at $25.01. 2.98 Million Shares were traded in the last trading session with an Average Volume of 2.11 Million Shares. The stock currently has a Market Capitalization of 4.1 Billion.
The New York Times Company is a global media organization dedicated to enhancing society by creating, collecting and distributing high-quality news and information. The Company includes The New York Times, NYTimes.com and related properties. It is known globally for excellence in its journalism, and innovation in its print and digital storytelling and its business model.
The stock traded between $16.95 and $26.91 over 1-Year time period showing its price to sales ratio of 2.42. New York Times Company (The) (NYSE:NYT) is currently showing an DECREASING volatility over a period of 10-Days while the 20-Days Volatility showing a DECREASING trend.
Right now, the stock has a 50-Day Simple Moving Average of $5.37 and 200-Day Simple Moving Average of $5.3. Its Price to Free Cash Flow is 0 and Price to Book of 4.21.
Analyst’s recommended the stock as 2.7 where 1 represents Strong Buy and 5 represents Sell.
In the last Quarter, New York Times Company (The) (NYSE:NYT) reported its Actual EPS of $0.17/share. The analysts offering Earnings Estimates for the company were believing that New York Times Company (The) could bring EPS of $0.15/share. The difference between Actual EPS and Estimated EPS was 0.02 Percent. Thus showing an Earnings Surprise of 13.3 Percent.
BioPharmX Corporation (NYSE:BPMX)
In the last trading session, BioPharmX Corporation (NYSE:BPMX) added its value by -1.14% closing at the price of $0.17. The stock currently has market capitalization of 34.58 Million, with average volume of 4.06 Million shares.
Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently BioPharmX Corporation (NYSE:BPMX) is showing beta of -0.61. This particular value of beta suggests that BioPharmX Corporation (NYSE:BPMX) has historically moved -61% for every 100% move in the benchmark, based on price level.
EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for BioPharmX Corporation (NYSE:BPMX) is at $-0.06.
The stock currently has RSI of 41.84. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.
BioPharmX Corporation is a specialty pharmaceutical company. The company focuses on the development of novel drug delivery products for women’s health, dermatology and otolaryngology markets. The Company’s product pipeline includes products in categories consists of prescription products, over-the-counter products and dietary supplements. Prescription products in development include molecular iodine pill for the treatment of breast pain associated with fibrocystic breast disease. OTC product pipeline includes a series of medicated bandages, nasal sprays and other products. Supplement product pipeline includes BioPharmX’s breast health pill. Its product candidates include BPX03 a molecular iodine tablet for the treatment of benign breast pain associated with FBC and cyclic mastalgia and BPX01 a non-lipophilic topical antibiotic for the treatment of acne. BioPharmX Corporation is headquartered in Menlo Park, California.
BioPharmX Corporation (NYSE:BPMX) topped its 52-week high price of $0.380 on 03/07/18 and 52-Week Low Price of $0.100 on 12/21/17. The Stock currently has P/E (price to earnings ttm) of 0 and Weekly volatility of 5.34% and monthly volatility of 6.52% respectively.